Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Condom warnings

This article was originally published in The Tan Sheet

Executive Summary

Statement clarifying that "contracting the human papilloma virus" can still occur "despite the use of condoms" would be required on all retail packages of condoms sold or distributed in California as of Jan. 1, 2001, under Assembly bill 2216 scheduled for hearing by the Committee on Health April 4. The state measure was introduced by Jim Battin (R) Feb. 24. On the federal level, an amendment to HR 1070 requiring HPV warnings to appear on condom labeling unanimously passed the House Commerce Committee on Oct. 29; the bill has yet to be considered on the floor (1"The Tan Sheet" Nov. 8, 1999, p. 9)

You may also be interested in...



Condom HPV Warning Would Be Required Under Cervical Cancer Bill

Condom labeling would be required to bear a warning that the devices do not provide adequate protection against the transmission of human papillomavirus (HPV) under an amendment to breast and cervical cancer treatment legislation pending in the House.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091010

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel